FGF6抗体;FGF6 Antibody—艾普蒂

+ +

•  

   

     Gel: 12%SDS-PAGE, Lysate: 40 μg, Lane 1-3: HepG2, Hela, 293T cell lysates, Primary antibody: P12467(FGF6 Antibody) at dilution 1/1100, Secondary antibody: Goat anti rabbit IgG at 1/5000 dilution, Exposure time: 45 seconds    

  
  

Fibroblast Growth Factor 6 (FGF6) is a member of the FGF family, which comprises 23 secreted signaling proteins involved in tissue repair, embryonic development, and metabolic regulation. FGF6. specifically, is encoded by the *FGF6* gene and shares structural homology with FGF23. It primarily binds to fibroblast growth factor receptors (FGFRs) with heparan sulfate as a cofactor, activating downstream pathways like MAPK and PI3K/AKT. FGF6 is highly expressed in skeletal muscle and plays a critical role in myoblast proliferation, muscle regeneration, and injury response. Dysregulation of FGF6 is linked to muscle pathologies, including muscular dystrophy, and certain cancers due to its mitogenic and angiogenic properties.

FGF6 antibodies are immunological tools designed to detect, quantify, or inhibit FGF6 in research and diagnostics. These antibodies are typically generated in hosts like rabbits or mice using recombinant FGF6 protein or peptide epitopes. They enable applications such as Western blotting, immunohistochemistry (IHC), ELISA, and functional studies to explore FGF6’s role in muscle homeostasis, cancer progression, or regenerative mechanisms. Monoclonal antibodies offer high specificity, while polyclonal antibodies detect multiple epitopes. Validation is crucial to ensure cross-reactivity avoidance with homologous FGFs (e.g., FGF9). Commercially available FGF6 antibodies aid in biomarker studies, therapeutic target validation, and understanding FGF6’s dual role in tissue repair and disease. Ongoing research focuses on its therapeutic potential in muscle-wasting disorders and as a cancer biomarker.